Aldosterone as a cardiovascular risk hormone

Endocrine Journal

Volumn 54, Issue 3, 2007, Pages 359-370

  Yoshimoto, Takanobu ^a   Hirata, Yukio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin; Mineralocorticoid receptor; Oxidative stress; Vascular

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; MINERALOCORTICOID RECEPTOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; EPITHELIUM; EPITHELIUM CELL; HEART INJURY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; REVIEW;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; EPITHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; RISK FACTORS;

EID: 34547114508     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.KR-80     Document Type: Review

References (88)

1. Tait SA, Tait JF (1998) The correspondence of S.A.S. Simpson and J.F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone). Steroids 63: 440-453.
2. Fuller PJ, Young MJ (2005) Mechanisms of mineralocorticoid action. Hypertension 46: 1227-1235.
3. Pascual-Le Tallec L, Lombes M (2005) The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 19: 2211-2221.
4. Rogerson FM, Fuller PJ (2000) Mineralocorticoid action. Steroids 65: 61-73.
5. Daugherty A, Cassis L (2004) Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 14: 117-120.
6. Horiuchi M, Akishita M, Dzau VJ (1999) Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613-621.
7. Touyz RM (2005) Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal 7: 1302-1314.
8. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273: 8890-8896.
9. Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, Marumo F, Hirata Y, Inagami T (1999) Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem 274: 36843-36851.
10. Eguchi S, Iwasaki H, Inagami T, Numaguchi K, Yamakawa T, Motley ED, Owada KM, Marumo F, Hirata Y (1999) Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells. Hypertension 33: 201-206.
11. Yoshimoto T, Fukai N, Sato R, Sugiyama T, Ozawa N, Shichiri M, Hirata Y (2004) Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology 145: 3331-3337.
12. Yoshimoto T, Gochou N, Fukai N, Sugiyama T, Shichiri M, Hirata Y (2005) Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells. Hypertens Res 28: 165-172.
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 348: 1309-1321.
15. Funder JW (2004) Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217: 263-269.
16. Rudolph AE, Rocha R, McMahon EG (2004) Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol 217: 229-238.
17. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863-1867.
18. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA, Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC (1993) Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20: 296-298.
19. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM (1990) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353: 40.
20. Nishikawa T, Omura M (2000) Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 54 (Suppl 1): 83s-85s.
21. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6: 907-913.
22. Halimi JM, Mimran A (1995) Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 13: 1801-1802.
23. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC (1996) Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27: 1039-1045.
24. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T (1995) Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18: 370-373.
25. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL (1993) Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 71: 17A-20A.
26. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82: 1730-1736.
27. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PW (2004) Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 43: 957-962.
28. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351: 33-41.
29. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 1831-1838.
30. Weber KT (2003) Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone. J Lab Clin Med 142: 71-82.
31. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364.
32. Brilla CG, Weber KT, Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1992) Reactive and reparative myocardial fibrosis in arterial hypertension in the rat: Remodeling of the rat right and left ventricles in experimental hypertension. Cardiovasc Res 26: 671-677.
33. Brown L, Duce B, Miric G, Sernia C (1999) Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 10 (Suppl 11): S143-S148.
34. Young M, Head G, Funder J (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269: E657-E662.
35. Rocha R, Funder JW (2002) The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970: 89-100.
36. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA, Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-H1810.
37. Rocha R, Stier CT Jr (2001) Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12: 308-314.
38. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3678.
39. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212-2216.
40. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M (2003) Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41: 955-963.
41. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M (2005) Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46: 1135-1139.
42. Delyani JA, Robinson EL, Rudolph AE (2001) Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 281: H647-H654.
43. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN (2002) Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106: 2967-2972.
44. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237: 268-275.
45. Tsai MJ, O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486.
46. Rupprecht R, Arriza JL, Spengler D, Reul JM, Evans RM, Holsboer F, Damm K (1993) Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol 7: 597-603.
47. Couette B, Jalaguier S, Hellal-Levy C, Lupo B, Fagart J, Auzou G, Rafestin-Oblin ME (1998) Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor. Mol Endocrinol 12: 855-863.
48. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A (1998) Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci USA 95: 2973-2978.
49. Seeler JS, Dejean A (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4: 690-699.
50. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, Nagasawa H, Nakajima T, Matsumoto T, Kato S (2002) Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol 22: 3698-3706.
51. White PC, Mune T, Agarwal AK (1997) 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135-156.
52. Funder JW (1995) Mineralocorticoid receptors and hypertension. J Steroid Biochem Mol Biol 53: 53-55.
53. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C (1990) ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 258: E649-E653.
54. Young MJ, Funder JW (1996) The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 271: E883-E888.
55. Sato A, Funder JW (1996) High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 137: 4145-4153.
56. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG (2003) Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93: 69-76.
57. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, Mabuchi H, Takeda R (1996) Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 81: 2797-2800.
58. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY, Takeda R (1995) Production of aldosterone in isolated rat blood vessels. Hypertension 25: 170-173.
59. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C (1998) Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273: 4883-4891.
60. Kayes-Wandover KM, White PC (2000) Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 85: 2519-2525.
61. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y, Sakamoto T, Yamamuro M, Saito Y, Nakao K, Yasue H, Ogawa H (2002) Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 87: 3936-3940.
62. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K (2001) Aldosterone production is activated in failing ventricle in humans. Circulation 103: 72-77.
63. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE (2004) Origin of aldosterone in the rat heart. Endocrinology 145: 4796-4802.
64. Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE (2004) Do human vascular endothelial cells produce aldosterone? Endocrinology 145: 3626-3629.
65. Liu H, Colavitti R, Rovira II, Finkel T (2005) Redox-dependent transcriptional regulation. Circ Res 97: 967-974.
66. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, Umesono K, Makino I, Tanaka H (1996) Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 98: 2469-2477.
67. Piwien-Pilipuk G, Ayala A, Machado A, Galigniana MD (2002) Impairment of mineralocorticoid receptor (MR)-dependent biological response by oxidative stress and aging: correlation with post-translational modification of MR and decreased ADP-ribosylatable level of elongating factor 2 in kidney cells. J Biol Chem 277: 11896-11903.
68. Rutter J, Reick M, Wu LC, McKnight SL (2001) Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293: 510-514.
69. Zhang Q, Piston DW, Goodman RH (2002) Regulation of corepressor function by nuclear NADH. Science 295: 1895-1897.
70. Young MJ, Moussa L, Dilley R, Funder JW (2003) Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144: 1121-1125.
71. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, Minami I, Iwashima F, Sakai H, Tateno T, Sato R, Hirata Y (2005) Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 336: 163-167.
72. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL (2002) Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40: 504-510.
73. Beswick RA, Dorrance AM, Leite R, Webb RC (2001) NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38: 1107-1011.
74. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL (2004) Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens 17: 597-603.
75. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL (2003) Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42: 737-743.
76. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y (2004) Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43: 841-848.
77. Somers MJ, Mavromatis K, Galis ZS, Harrison DG (2000) Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 101: 1722-1728.
78. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002) Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 161: 1773-1781.
79. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC (2001) Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786.
80. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C (1999) Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33: 981-986.
81. Xiao F, Puddefoot JR, Barker S, Vinson GP (2004) Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 44: 340-345.
82. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109: 2792-2800.
83. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M (2005) Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97: 434-442.
84. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H (2001) Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104: 137-139.
85. Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, Fukai N, Shichiri M, Hirata Y (2005) Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146: 3900-3906.
86. Dzau VJ (1993) Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol 88 (Suppl 1): 1-14.
87. Miyazaki M, Okamura T, Toda N (1988) Role of vascular angiotensin converting enzyme in hypertension. J Hypertens (Suppl 6): S13-15.
88. Okunishi H, Kawamoto T, Kurobe Y, Oka Y, Ishii K, Tanaka T, Miyazaki M, Miyazaki M, Okamura T, Toda N (1991) Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat: Role of vascular angiotensin converting enzyme in hypertension. Clin Exp Pharmacol Physiol 18: 649-659.